clinical trial · NCT07300150
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
PAQ Therapeutics, Inc.·phase1·recruiting·n = 195
Colorectal CancerPancreatic CancerNon-Small Cell Lung CancerSolid TumorPT0511Cetuximab
brief summary
The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal cancer (CRC).
started
Nov 21, 2025
primary completion
Oct 18, 2028
completion
Oct 18, 2028
last updated
May 7, 2026
official title
A Phase 1, Open-label Dose Escalation and Expansion Study OF PT0511 in Participants With KRAS Mutated OR Amplified Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol